-- Proceeds Will Fund Completion of GT-30
Trial of Personalized Therapeutic Cancer Vaccine in Liver Cancer
--
-- Shanghai-based SHC Added to Geneos' Investor
Syndicate --
PLYMOUTH
MEETING, Pa., Sept. 27,
2023 /PRNewswire/ -- Geneos Therapeutics, a clinical
stage biotherapeutics company focused on the development of
personalized therapeutic cancer vaccines (PTCV), today announced
that it has completed its Series A3 financing round with an
additional investment of $5 million,
totaling $10 million. This investment
adds Shanghai Healthcare Capital (SHC) to Geneos' investor
syndicate. Dr. Jing Bao will join as
a board observer, bringing extensive expertise in the
pharmaceutical industry and with global clinical trials.
"We are pleased to add SHC to our investor syndicate and Dr. Bao
to our team. The depth of knowledge the SHC team brings as well as
their network in China will be
invaluable to Geneos, especially as we pursue hepatocellular
(liver) cancer as our initial target," stated Niranjan Sardesai, PhD., president and chief
executive officer of Geneos Therapeutics.
"The results that Geneos has achieved to date in the clinic with
its personalized therapeutic cancer vaccine are impressive, and we
are pleased to support Geneos' further clinical development of this
important treatment," stated Jing
Bao, MD, partner of SHC.
Proceeds Will Fund Completion of Phase 1b/2a GT-30 Program
GT-30 is evaluating
the safety, and efficacy of PTCV (GNOS-PV02 plus plasmid-encoded
IL-12) administered in combination with the immune checkpoint
inhibitor pembrolizumab, in 36 patients with unresectable or
metastatic hepatocellular carcinoma (HCC) who progress on, or are
intolerant to, first-line tyrosine kinase inhibitors (sorafenib or
lenvatinib). Study enrollment completed in June of this year with
the top-line safety and clinical response data from the complete
cohort of 36 patients is anticipated by the end of the year.
https://classic.clinicaltrials.gov/ct2/show/NCT04251117.
About Shanghai Healthcare Capital
With the approval of
the Shanghai municipal government,
Shanghai Industrial Investment (Holdings) Co., Ltd. (SIIC)
established Shanghai Healthcare Capital (SHC) with market-oriented,
professional and international operation principles. The total fund
scale of SHC reached around 7 billion
USD. By making full use of the comprehensive advantages of
Shanghai, Shanghai Healthcare
Capital utilizes the industrial resources to create a leading
innovative investment platform in the life science industry based
in Shanghai and Hong Kong, with strong links to the Yangtze
River Delta and the world, so as to assist Shanghai to establish a top tier biomedical
research and development center and manufacturing center in the
world. The fund focuses on breakthrough biologics, innovative
chemical drugs, high-end medical devices and diagnostics, and
innovative business platforms, not only through the integration of
capital and industrial resources but also international and
domestic operations. For more information, please visit
www.siicshc.com.
About Geneos Therapeutics
Geneos Therapeutics, a privately held, clinical stage
biotherapeutics company, believes that the company's personalized
therapeutic cancer vaccines (PTCVs) may serve an important role in
new immunotherapeutic paradigms for cancer. The company's approach,
using its proprietary GT-EPIC™ platform, is to target neoantigens
(abnormal mutations produced by cancer cells) from individual
patient tumors to develop novel and uniquely personalized
treatments for cancer. Planning is underway for a potentially
registrational clinical trial in advanced hepatocellular carcinoma.
Geneos' experienced management team has a track record of success
in building immunotherapy-based companies. For more information,
please visit www.geneostx.com.
This press release contains certain forward-looking
statements relating to our business, including our plans regarding
the development of personalized therapeutic cancer vaccines, our
expectations regarding our research and development programs,
including the planned expansion and conduct of clinical trials and
the availability and timing of data from those trials, and the use
of our capital resources. Actual events or results may differ from
the expectations set forth herein. There can be no assurance that
any product candidate in Geneos' pipeline will be successfully
developed, manufactured or commercialized, that final results of
clinical trials will be supportive of regulatory approvals required
to market licensed products, or that any of the forward-looking
information provided herein will be proven accurate.
Forward-looking statements speak only as of the date of this
release, and Geneos undertakes no obligation to update or revise
these statements, except as may be required by law.
This press release does not constitute an offer to sell or
the solicitation of an offer to buy any securities.
View original
content:https://www.prnewswire.com/news-releases/geneos-therapeutics-closes-its-series-a3-financing-with-investment-of-5-million-301941077.html
SOURCE Geneos Therapeutics, Inc.